3-D Matrix, Ltd. (DMTRF)
OTC
Healthcare
Biotechnology
$2.42
▲ +0.00%
Market Cap
$310.4M
Sector
Healthcare
Industry
Biotechnology
Beta
0.99
52-Wk Range
1.91-3.96
CEO
Toshihiko Amanuma
Country
JP
Currency
USD
3-D Matrix, Ltd. operates in the Biotechnology industry of the Healthcare sector, headquartered in Tokyo, TY, JP. The stock last traded at $2.42, up 0.00% on the session, giving a market capitalisation of $310.4M. On trailing twelve-month figures it carries a trailing P/E of 9.19, a net margin of 31.0%. Its beta of 0.99 implies it has historically moved less than the broad market.
Valuation & profitability (TTM)
P/E
9.19
Price / Sales
3.00
Price / Book
4.95
EV / EBITDA
13.64
Gross margin
79.5%
Operating margin
15.3%
Net margin
31.0%
Return on equity
—
Debt / equity
0.08
Current ratio
4.08
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
129
IPO date
2013-06-19
Headquarters
Tokyo, TY, JP
About 3-D Matrix, Ltd.
3-D Matrix, Ltd. specializes in pioneering self-assembling peptide technology. Its flagship product, PuraMatrix, is an innovative self-assembling peptide hydrogel with diverse applications across medical fields, including regenerative medicine, cell therapy, advanced drug delivery systems, and surgical interventions. This Tokyo-based firm was established in 2004.
More research on DMTRF
Open full interactive analysis & DCF →